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STUDY PROTOCOL Open Access
Integrating pediatric TB services into child
healthcare services in Africa: study protocol
for the INPUT cluster-randomized stepped
wedge trial
Lise Denoeud-Ndam1* , Rose Otieno-Masaba2, Boris Tchounga3, Rhoderick Machekano4, Leonie Simo3,
Joseph Phelix Mboya2, Judith Kose2,5, Patrice Tchendjou3, Anne-Cécile Zoung-Kanyi Bissek6,
Gordon Odhiambo Okomo7, Martina Casenghi1, Jennifer Cohn1, Appolinaire Tiam4,8 and the INPUT Study Group
Abstract
Background: Tuberculosis is among the top-10 causes of mortality in children with more than 1 million children
suffering from TB disease annually worldwide. The main challenge in young children is the difficulty in establishing
an accurate diagnosis of active TB.
The INPUT study is a stepped-wedge cluster-randomized intervention study aiming to assess the effectiveness of
integrating TB services into child healthcare services on TB diagnosis capacities in children under 5 years of age.
Methods: Two strategies will be compared: i) The standard of care, offering pediatric TB services based on national
standard of care; ii) The intervention, with pediatric TB services integrated into child healthcare services: it consists
of a package of training, supportive supervision, job aids, and logistical support to the integration of TB screening
and diagnosis activities into pediatric services. The design is a cluster-randomized stepped-wedge of 12 study
clusters in Cameroon and Kenya. The sites start enrolling participants under standard-of-care and will transition to
the intervention at randomly assigned time points. We enroll children aged less than 5 years with a presumptive
diagnosis of TB after obtaining caregiver written informed consent. The participants are followed through TB
diagnosis and treatment, with clinical information prospectively abstracted from their medical records.
The primary outcome is the proportion of TB cases diagnosed among children < 5 years old attending the child
healthcare services. Secondary outcomes include: number of children screened for presumptive active TB;
diagnosed; initiated on TB treatment; and completing treatment. We will also assess the cost-effectiveness of the
intervention, its acceptability among health care providers and users, and fidelity of implementation.
Discussion: Study enrolments started in May 2019, enrolments will be completed in October 2020 and follow up
will be completed by June 2021. The study findings will be disseminated to national, regional and international
audiences and will inform innovative approaches to integration of TB screening, diagnosis, and treatment initiation
into child health care services.
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Background
Childhood tuberculosis
In 2016, more than 1 million children (< 15 years) had
tuberculosis (TB) disease worldwide over 253,000 of
whom died, making TB one of the leading causes of
death in children [1, 2]. Younger children and children
with HIV co-infection are at the highest risk of progres-
sing to disease after infection, developing disseminated
forms of TB and dying [3–5]. Africa accounts for about
one-third of all pediatric TB cases with an incidence of
29–34/100,000, which is double the global average [2, 6].
The main challenge in childhood TB is the difficulty in
establishing an accurate diagnosis of active TB since
symptoms are not specific, children cannot easily pro-
duce sputum, and they mostly develop paucibacillary
disease [5, 7]. The Xpert MTB/RIF assay is a major ad-
vance for diagnosis of TB [8]. Sensitivity of Xpert is
lower in children than in adults, however the assay does
help to increase the proportion of children with a
laboratory-confirmed diagnosis of TB [9]. However, its
use is limited by children’s difficulty to produce sputum.
These challenges in case detection and diagnosis are the
main reasons why only 39% of estimated pediatric TB
cases are notified to national TB programs (NTPs), with
the remaining children undiagnosed or unreported [2].
Rationale for the INPUT study
In many sub-Saharan African countries, diagnosis and
treatment of children with active TB is centralized at the
high level of care and provided in separate TB units.
This adds to the list of barriers to identification of cases
and scale up of treatment of children with TB disease.
Pediatric services such as Maternal, Neonatal and Child
Healthcare (MNCH)/under-5 services, outpatient clinics
for children, pediatric ART services, and nutrition re-
habilitation services may represent a first entry point for
children with TB disease in many countries. The import-
ance of linking TB prevention and care to maternal and
child health programs has been recognized [10].
Yet, very limited data are available on the feasibility of
integration of TB care in the child health care services
and its impact on pediatric TB case detection, cascade of
TB care, and treatment outcomes. Data from the HIV
context have demonstrated that integration of HIV ser-
vices into other health services is feasible, does not com-
promise care and results in lower rates of loss-to-follow-
up [11, 12]. Similarly, there is growing evidence that
integrating TB services into HIV services results in good
quality care and improved retention in adults [13, 14]. In
a recent Cochrane review synthesizing available evidence
on the impact of interventions to increase tuberculosis
case detection in adults at primary healthcare or
community-level services, the authors reported an in-
crease in TB case detection in short term [15]. The effect
of active case finding on treatment outcome needed fur-
ther evaluation since most studies included in Cochrane
were not powered to answer this question.
Further, the DETECT study in Uganda evaluated a
mixed intervention combining decentralization of TB care
in primary health care facilities and implementation of TB
screening at community level. It showed that the strength-
ening of TB services at peripheral health facilities was as-
sociated with increased case finding, improved treatment
outcomes and the successful implementation of contact
screening and management [16].
However, evidence on the integration of TB care in
other child health services is limited. One retrospective
study showed the feasibility of intensified case finding ef-
forts in children at nutrition rehabilitation centers. They
found that out of the 440 children with severe acute
malnutrition screened, 39 (8.8%) were diagnosed with
TB. Among these, 87% initiated TB treatment [17]. A
study in Ethiopia examined intensive screening of chil-
dren under-5 years old in MNCH clinics and the results
demonstrated the feasibility of this approach, though its
impact could not be assessed due to the absence of a
comparison group [18]. A recent publication assessed
the impact of systematic verbal screening at pediatric
outpatient department, with clinical evaluation and free
diagnostics, on childhood TB detection in rural Pakistan.
These activities resulted in a three-fold increase in
pediatric TB case detection, thus showing that this strat-
egy can identify children with TB who may otherwise be
missed in rural health settings [19].
Methods/design
Hypothesis and aims
We hypothesize that the integration of TB services into
non-TB pediatric healthcare services; through increasing
the capacity of all health care workers to diagnose chil-
dren with TB, improving intra and inter-facility linkages
and coordination and improving patient-centered care
and support, will result in improved case detection and
treatment outcomes in children less than 5 years of age.
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We define TB services as active case finding, diagnosis
of active TB disease and initiation on treatment fr drug-
sensitive TB disease.
The primary objective of this study is to assess the ef-
fect of integrating TB screening, diagnosis and treatment
services in child health care services compared to stand-
ard of care in the second level hospitals (hubs) and their
attached health centers (spokes), on the proportion of
TB cases diagnosed among children < 5 years old (the
number of children who are clinically or bacteriologic-
ally diagnosed with TB over the total number of children
attending the child healthcare services).
Secondary objectives are:
 To compare the outcomes of the intervention
(integrating TB services intervention into child
health care services) compared to routine, standard
of care on the cascade of care for diagnosis of drug
sensitive tuberculosis (DS-TB) and treatment
initiation and completion, overall and disaggregated
by pediatric health services and level of care
 To determine the number of children needed to
screen in order to diagnose one pediatric TB case
through integration of TB services in various child
health services.
 To describe the characteristics of children diagnosed
with Active TB disease.
 To describe WHO-defined TB treatment outcomes
and associated factors.
 To determine the rate of HIV infection among
children with presumptive and confirmed pediatric
TB diagnosis.
Qualitative objectives are:
 To assess caregivers’ acceptability and perceptions
about integrated pediatric TB services;
 To understand the effect of the integrated TB
service model on service delivery in the non-TB
pediatric health services;
 Through community workers, to explore the
community knowledge about pediatric TB and
perceptions about the integrated pediatric TB
services.
A cost-effectiveness analysis will estimate the costs
and benefits associated with TB care under the interven-
tion and standard of care and determine incremental
cost effectiveness of the intervention, both from a health
system and patient perspective.
Study design
We are conducting a multi-country stepped-wedge
cluster-randomized controlled trial to compare two
strategies for case detection and management of tuber-
culosis in children under the age of 5 years: i) The stand-
ard of care offers pediatric TB services based on current
routine approach (national standard of care); ii) The CaP
TB intervention will offer pediatric TB services inte-
grated into key child healthcare services.
In this study, a stepped wedge design [20] has been
preferred to parallel cluster trial for the following rea-
sons: It allows every site participating in the study to
eventually be exposed to the CaP TB intervention, which
is in line with the scale up of CaP TB activities, and
more acceptable for the MoHs. The phased roll-out of
CaP TB activities provides logistical advantages. The
intra-cluster correlation is anticipated to be high and
cluster size large so that a stepped wedge design is likely
to be more efficient than the simple parallel cluster de-
sign [21], and will require a smaller number of clusters
[22]. Finally, stepped-wedge design allows for the control
of trends over time due to external changes in the way
care is delivered, for example changes in national
guidelines.
In INPUT study, the randomization unit or cluster is
defined as a district or sub-district hospital (the hub)
and some of its attached primary health care centers
(spokes) that refer patients or samples to these facilities
for TB diagnosis. A randomization list prepared by the
biostatistician in EGPAF determines time of enrollment
of each of these sites into the intervention phase.
Figure 1 shows the stepped wedge study design. Justifi-
cation for total number of steps, number of clusters per
step and duration of steps is given in the “sample size”
section.
Study sites and participants
The study is being implemented in Kenya and Cameroon.
These countries were purposively selected based on the
TB burden, geographical location and representativeness
of the epidemic in sub-Saharan Africa.
The planned total number of sites is 12 hospitals
(hubs), 6 in each country, with up to two purposively se-
lected health centers (spokes) per hospital selected based
on their TB case load and accessibility from the hub.
Study hubs were purposively selected in collaboration
with the NTPs and MoH in Cameroon and Kenya ac-
cording to the following criteria:
– Sites where regions or counties where CaP TB was
being implemented.
– At least 6000 pediatric visits per year altogether in
the district/county hospital and related selected
health centers. Based on available data in the two
countries, we assumed each site may be able to see
on average 20 children with presumptive TB per
month and diagnose at least 12 pediatric TB cases
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per year (one per month), under the standard-of-
care.
– Routine adult TB diagnosis and treatment available
onsite.
– No previous or ongoing introduction of
interventions for integration or increasing coverage
of TB services, apart from NTP interventions that
are considered as standard-of-care throughout the
whole study duration.
According to these criteria, the selected district hospi-
tals in Cameroon are Soa, Akonolinga, Loum; Mbouda,
Dschang and Foumban. In Kenya, the selected district or
sub-district hospitals are Ndhiwa, Kendu, Homa Bay
county hospital, Kakuma mission hospital, Lopiding sub-
county hospital and Lokitaung’s subcounty hospital.
Each study site is allocated a unique site identification
number.
The study population consists of all the children aged
less than 5 years who present for care in the selected
study district hospitals and selected attached heath cen-
ters. These children serve as the denominator to calcu-
late the proportion of cases diagnosed in child
healthcare services in each facility (the primary outcome
of the study).
Children who meet all eligibility criteria are eligible for
enrolment in the prospective follow-up of the study after
the study nurse obtains written informed consent from
caregivers.
Inclusion criteria are:
– Children < 5 years old.
– Presumptive pulmonary or extra-pulmonary TB
case: symptoms or clinical signs suggestive of active
TB disease.
– TB diagnostic investigations initiated.
– Commitment to take treatment in the clinic of
enrolment or another INPUT study site.
– Parental/caregiver consent for the child to
participate in the study.
Exclusion criterion is:
– Children who are TB contacts but without
symptoms or signs of active TB.
Standard-of-care of TB services in study sites
In both countries, TB care is currently delivered in one
place called the TB unit or TB clinic. In Cameroon, TB ser-
vices are offered only at health facilities where a doctor is
in service and TB screening is not currently recommended
nor done systematically at each entry point. While in
Kenya TB services are offered at primary health care level,
TB screening is recommended at every entry point, chil-
dren and adults with presumptive diagnosis of TB all go to
TB unit for diagnostic work-up and treatment.
According to national guidelines in Cameroon and
Kenya, TB diagnosis in children involves the screening
Fig. 1 INPUT study stepped-wedge design. *Estimation based on the hypothesis of 2 cases diagnosed per 1000 children seen under standard-of-
care and doubling under intervention
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of children who present in health facility for symptoms
of active TB disease: non-remitting cough for more than
2 weeks, fever for more than 10 days, night sweats for
more than 2 weeks, fatigue, reduced playfulness or de-
creased activity, weight or appetite loss or failure to
thrive during the last 3 months. Symptomatic children
are identified as TB presumptive and should start TB in-
vestigations in the TB clinic, including routine specimen
collection and testing. In Kenya, Xpert testing is avail-
able as standard-of-care in most district hospitals, this is
not the case in Cameroon.
Children with presumptive TB and for whom all TB la-
boratory diagnostic tests were negative or investigations were
not done, undergo clinical and if possible radiological investi-
gation as per national guidelines in Cameroon and Kenya.
Ultimately, the clinician in the TB clinic can make a clinical
diagnosis of TB based only on history and physical examin-
ation findings, including clinical response to a trial of broad-
spectrum antibiotics. Treatment initiation and follow-up take
place in the TB clinic.
Intervention under evaluation: the CaP TB intervention
package
The CaP TB intervention has been defined for every
level of care. It involves a package of training, supportive
supervision, monitoring tools, job aids and logistical sup-
port (e.g. creation or strengthening of referral networks,
sample transport) for the integration of TB activities into
non-TB child healthcare services.
These components are specifically oriented towards
integration of screening and diagnosis services into child
health care services:
– Integration of the screening into all the child health
care services with introduction of a specific case
detection tool and updated presumptive TB register.
 To improve symptom screening in the facilities,
trained cough monitors are placed in all the
study sites and serve as lay health workers who
screen patients in waiting rooms. They
accompany children with presumptive TB
diagnosis to health care providers.
– Improvement of diagnosis capacity (according to the
national guidelines or WHO/UNION recommended
approach to TB diagnostic in children [23, 24] and
their integration in all levels of care and all services:
 Strengthened use (in Kenya where it already
exists) or introduction (in Cameroon where it
needs to be developed) of a diagnostic algorithm
for the diagnosis of TB in children, especially at
primary health care level, where capacities for
biological diagnosis are often limited.
 Trainings for specimen collection, including
gastric aspirates, nasopharyngeal aspirates,
induced sputum and lymph node aspiration,
especially at district hospital level, with
integration into the different pediatric entry
points including the inpatient ward for
hospitalized children.
 Support for Xpert testing of all the specimen
collected, either on site or through sample
referral, with procurement of GeneXpert devices
and Xpert cartridges.
 Support for X-rays completion: use of transport
vouchers for children to go to the referral site for
X-ray if needed.
Children who are diagnosed with TB disease are initi-
ated on anti-TB treatment at the point of diagnosis.
Drug dispensation, drug refill and follow-up take place
at the TB unit in hub sites, or as designed through rou-
tine system in spoke sites.
Sample collection methods and concomitant care
Sputum and other laboratory specimens such as gastric lav-
age, induced sputum, nasopharyngeal aspirate and lymph
node aspiration are collected from children and processed
according to manufacturer protocols and national guidelines.
Specimens are tested using Xpert MTB/RIF assay (Ce-
pheid, Sunnyvale, California, USA). Xpert testing and in-
terpretation of results are carried out according to
manufacturer instructions. Sputum smear microscopy is
performed following the Ziehl-Nielsen method. At least
100 high power fields will be read before returning a
negative result. Results are reported as follows: No acid-
fast bacilli seen, exact number of bacilli seen if less than
10 in 100 fields, + if 10–100, ++ if 100–1000, +++ if
> 1000 per 100 fields.
Sputum samples for culture are processed according to
national standard of care. This is not part of CaP TB project
but will be carried out with support from national program.
All children who have positive TB symptoms and who
are HIV exposed or whose exposure status is unknown
will be screened for HIV with age-specific test. For chil-
dren who are still breastfeeding or young infants aged less
than 12months, HIV diagnosis will be done using the Ce-
pheid/Alere point of care qualitative test while older chil-
dren who have stopped breastfeeding for more than 6
weeks will be tested for HIV using rapid test according to
national standard of care. All HIV laboratory testing will
be performed per the routine MoH protocols.
Treatment of active TB will follow national and WHO
guidelines during both the standard-of-care and inter-
vention phase. During intensive phase of treatment and
as per the current WHO guidelines the treatment will be
dispersible fixed dose combinations of isoniazid-
rifampicin-pyrazinamide associated with ethambutol and
during the continuation phase the treatment will be
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isoniazid-rifampicin. The duration of the treatment will
depend on the type of TB disease (pulmonary or extra-
pulmonary) and will follow national guidelines. Typic-
ally, the treatment will last 6 months in pulmonary TB
and will extend to 1 year for TB meningitis or osteo-
articular meningitis.
Although not part of the study, MDR and/or XDR TB
cases and cases needing additional care will be treated in
accordance to national guidelines. Whenever possible,
patients with confirmed MDR and/or XDR TB diagnosis
will be documented in order for the study team to calcu-
late the rate MDR/XDR among the children.
Evaluation activities and data collection processes
Trained study nurses are present in each study cluster.
They are responsible for the screening, consent and en-
rolment processes, collection and maintenance of study
records and data, in the hubs and their related spokes.
Different processes for data collection have been iden-
tified, as shown in the study flow-chart (Fig. 2). For chil-
dren attending pediatric health care services, routine
aggregated data are collected to define the number of
children attending the facility. This will serve as denom-
inator to calculate the proportion of cases diagnosed in
the facility.
The second process involves prospective, longitudinal
follow-up for children with presumptive diagnosis of TB,
until confirmed diagnosis, treatment initiation and com-
pletion. Figure 3 (SPIRIT diagram) outlines the study
procedures for these children. This prospective follow-
up involves a specific electronic case report form to
document all the cascade of TB care. Data clear from
identifiable information are collected and entered using
electronic tablets by direct data entry into a database
that has been designed specifically for this study and
stored on a secure web-based server.
In both standard-of-care and intervention phases, site
clinicians notify the study nurse of all children poten-
tially eligible for enrolment. In addition, the study nurse
regularly reviews the existing registers in the sites to ex-
tract anonymous screening information about children
with presumptive TB: service where seen, age, gender,
reason for coming, date of visit. Study nurses approach
mothers or caregivers of children who have a diagnosis
of presumptive TB on the day of presentation or as soon
as possible thereafter to screen the child for eligibility as
per inclusion criteria and enroll them after obtaining
written consent.
Then, diagnosis, treatment and monitoring activities
are scheduled according to the routine of TB care. The
study nurse collects data prospectively upon diagnostic
work-up (clinical, laboratory and X-ray findings if done).
Children are initiated on treatment by the healthcare
providers on site and the study nurse prospectively
collects data from treatment reports. Similarly, children
coming monthly to the study sites for treatment refill
are monitored by the healthcare providers as usual, and
the study nurse takes this opportunity to collect follow-
up data. Ideally, follow-up will continue until 2 months
after treatment completion but the maximum follow-up
duration is 12–14months. The duration of follow-up is
determined at treatment initiation based on the type of
TB diagnosis. However, some reasons may lead to the
interruption of monitoring (referral of the child, serious
adverse event, death, loss to follow-up). In all cases, the
date and reasons for the interruption will be collected in
the report form.
Enrolled children who are determined not to have TB
are followed during diagnostic procedures then termi-
nated from the study once they are determined not to
have active TB.
For children with a missed appointment for TB rou-
tine services, the in-country routine procedures for tra-
cing patients on TB care are followed, including phone
contact, household visit of community workers, or any
other mean according to national guidelines. In addition
to these routine procedures implemented by the health
facility staff, the study nurse also keeps a contact log
with phone numbers (consent is sought for this) and
may contact the caregiver to remind him of the appoint-
ment in TB care. If the child does not attend the routine
TB visit within a month of the planned schedule, the
visit is recorded as a missed visit.
In case the child comes to the study site for an un-
scheduled visit caused by an illness during his follow-up,
the study nurse collects clinical and laboratory data from
medical reports to document the nature and severity of
the disease.
The study nurses also collect information on how the
TB activities are being managed by the healthcare pro-
viders on site, both during the standard-of-care and the
intervention period, as a measurement of the fidelity of
implementation. A specific log had been designed for
this purpose where deviations between practice and
guidelines are recorded and shared prospectively with
the CaP TB program team in order to improve practices.
Outcomes
The primary outcome is the proportion of children diag-
nosed with TB defined as the number of pediatric TB
cases diagnosed over the number of children attending
the child healthcare services during the study period.
Main secondary outcomes include:
– Proportion of children screened for TB among the
total number of children attending the child
healthcare services.
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– Proportion of children diagnosed with TB
(bacteriologically or clinically) among presumptive
TB cases, overall and disaggregated by HIV status
and nutrition status.
– Time from screening to clinical or bacteriologic
diagnosis.
– Time from diagnosis to treatment initiation.
– Proportion of cases with a bacteriologically
confirmed diagnosis.
– Treatment outcomes for patients initiated on
treatment according to WHO categories, with a
focus on treatment completion rate.
– Cost-effectiveness from a health system perspective,
as US dollars per disability-adjusted life-year (DALY)
averted.
– Comprehensive understanding of caregivers’
perceptions and patients’ and communities’
acceptability of receiving integrated pediatric TB
services within pediatric care.
Adverse events
Parents/caregivers are informed of any side effect which
could be associated with TB diagnosis procedures, espe-
cially invasive sample collections (gastric aspirate, lymph
node fine needle aspiration, CSF collection, ascites collec-
tion, nasopharyngeal aspirate), and with TB treatment.
The investigators describe adverse events occurring
during follow-up of children in a specific section of the
case report form.
Fig. 2 INPUT study flow-chart
Denoeud-Ndam et al. BMC Public Health          (2020) 20:623 Page 7 of 12
Serious adverse events as defined by ICH [25] or unex-
pected adverse events are reported to the ethics commit-
tees as per their guidance.
Since drugs dispensed during the study are part of na-
tional standard of care, children who develop adverse re-
actions are managed according to national standard of
care, according to the national pediatric TB guidelines in
Kenya and ad-hoc guidelines in Cameroon. The study
nurse collects outcome data from clinical and laboratory
reports.
Risks and benefits for participants
Patients who utilize CaP TB supported facilities in the
intervention phase benefit from better access to TB ser-
vices as part of the general CaP TB program implemen-
tation. There is no additional benefit to study
participants.
Risks to all participants is minimal. Potential risks in-
clude the potential for unintended disclosure of mother/
caregiver and infant’s TB infection status and for those
who are HIV infected their HIV status.
Fig. 3 INPUT study SPIRIT flow diagram. a Allocation done at cluster level prior to enrolment of participants, according to stepped-wedge
design. b Ideally, simple TB infection treatment will last for six months, but for TB meningitis, osteo-articular TB or cases that do not respond to
treatment appropriately, treatment may be extended to 12 months. All Information on treatment follow-up visits will be recorded as they occur.
At least monthly visits will be planned. Information on additional visits, when the child comes for intercurrent illnesses, will also be recorded. c If
any new results are collected
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Children enrolled in the INPUT study are identified by
their unique study identifier, and data collection and
forms are linked to the patient using this unique identi-
fier only. All study documents are maintained by the
study team in a locked cabinet in an office with limited
access. Following study completion and all analyses,
paper-based study documents for all data collection ac-
tivities will be destroyed after 7 years.
Caregivers may also feel discomfort in answering some
of the interview questions such as those to child’s expos-
ure to TB infection at home. Interviews are conducted
in private areas free from general view and out of hear-
ing reach. Study staff is thoroughly trained on interview-
ing techniques in general and those related to this study
in particular.
Sample size
The total number of clusters enrolled in this study has
been determined under three assumptions: 1) the ex-
pected “sample size” of clusters, which is the number of
children seen per month in each cluster; 2) the expected
baseline “detection rate”, which is the proportion of
cases diagnosed on the total number of children, during
the standard-of-care phase; and 3) the “effect size” of the
intervention which is the expected increase in detection
rate between standard-of-care and intervention phase.
According to baseline records, we estimate that the
number of consultations in children less than 5 years of
age will be at least 500 per month in each cluster. We
assume that at least 2 children will be diagnosed with
TB per 1000 children attending the child health care ser-
vices, under standard-of-care. Published studies on
interventions to enhance case detection in adults dem-
onstrated an effect of the intervention of 50% [15]. How-
ever, it is well known that under-reporting of child TB
cases is much more prevalent than adult TB cases [2],
and thus we believe it will be more subject to improve-
ment. Indeed, whereas the incidence of TB in children is
expected to be 10 to 12% of the total number of TB
cases in a particular country, the notified TB cases in
children represents only 6% of the total number of TB
cases in Cameroon and Kenya. We designed the study
according to an expected effect size ranging between 50
and 100%.
Based on a stepped-wedge design, with 2000 children
attending consultations during each four-month step of
the study, four randomly selected study sites per step
and 12 sites in total (three steps in the study), and an
ICC correlation of 0.001, we will have 96.5% power to
see a doubling in the case detection from two to four
per 1000.
With this design and assumptions, we expect to follow
300 confirmed pediatric TB cases during the whole
study duration. Current TB treatment completion rates
in routine care are estimated at least at 70%. With 96
cases expected under standard-of-care and 192 cases
under intervention, the power will be 80% to detect a
20% increase in completion rate.
Randomization and blinding
The randomization sequence was generated by the study
biostatistician using Stata 15.0 statistical software, with
stratification by country. In each country, two sites were
allocated to cross into the intervention after 4 months
under standard-of-care phase, 2 after 8 months under
standard-of-care, and 2 after 12 months under standard-
of-care. The allocation sequence remains concealed from
all investigators during the first 3 months of the study,
so that all sites start under standard-of-care blinded of
when the intervention phase will start. Then, the biostat-
istician discloses to Principal Investigators which four
sites in the two countries have been randomized to start
the intervention in the first step (see Fig. 2). The four
sites undergo a transition phase of 1 month with train-
ings before crossing to the intervention phase. All other
sites continue in the standard-of-care, still blinded on
the time when they will start the intervention, until the
last month before the next step. The one-month notice
given before starting into the transition phase will allow
sites to adequately plan for trainings in the study sites.
The study design does not allow the site investigators
to be blinded after assignment to interventions.
Statistical considerations
In a stepped wedge study, exposed (intervention) and
unexposed (standard-of-care) observation periods take
the place of “arms” in parallel cluster trials. Thus, the
distribution of outcomes across unexposed observation
periods is compared with that across the exposed obser-
vation periods [20, 21].
Characteristics of the individuals and clusters will be
summarized by exposure status (intervention versus
standard-of-care period) to assess for potential selection
biases and lack of balance. These characteristics will also
be compared by steps. This will include the numbers ana-
lyzed, the average cluster size, cluster characteristics (in
terms of TB care cascade), and important patient charac-
teristics (TB treatment outcomes). All comparisons will be
performed with a level of significance alpha of 5%.
Following an intention to treat principle, clusters will
be analyzed according to their randomized crossover
time irrespective of whether crossover was achieved at
the desired time. In addition, we will carry on per proto-
col analyzes where the clusters will be analyzed accord-
ing to the real timing on which the crossover actually
occurred.
Data collected during the one-month transition phase
from standard-of-care to intervention will not be
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considered in the analysis of outcomes, in order to
minimize contamination between study periods.
We will estimate the TB detection rates for each clus-
ter during each step. We will then summarize the detec-
tion rates by intervention period (standard-of-care
versus integration) and display the summaries using
graphs. To estimate the effect of integration on TB de-
tection rates (i.e., proportion of cases diagnosed), we will
use generalized linear mixed Poisson models. The effect
will be presented as rate ratio and associated 95% confi-
dence interval.
We will use time to event survival analysis approaches
with frailties to estimate the effect of the intervention on
treatment completion. This approach allows us to ac-
count for TB patients lost to follow-up or who transfer
to other facilities while estimating treatment completion
rates. In addition, we will use descriptive analysis to as-
sess the fidelity of the implementation of the interven-
tion over time and secondary outcomes that are likely to
be infrequent and thus with limited power to detect
differences.
Cost-effectiveness and qualitative components
Methods used for the qualitative component and the
cost-effectiveness component of the study are not cap-
tured in this manuscript. The latter are detailed in a sep-
arate Health Economics Analysis Plan [26].
Time period for the study
Participants are planned to be recruited from May 2019
until October2020, and follow-up will be completed by
June 2021. Then, results will be analyzed and shared as
described in dedicated parts of the protocol, with publi-
cations expected end 2021 / early 2022. The study is
planned to last for 3 years overall.
Discussion
The INPUT stepped-wedge cluster-randomized trial has
the potential to provide new and strong evidence on the
effectiveness and feasibility of innovative approaches to
integration of child TB care into pediatric entry points.
To ensure the robustness of the study, good clinical
practice requirements will be met. Research staff in the
field is under the supervision of the country principal in-
vestigator, who provides direct oversight and monitoring
of specific research activities. Before the study starts, the
study research teams has been trained on the protocol,
SOPs, data collection and standard study monitoring
tools. All study team members were trained in Human
Subjects Protection and signed a confidentiality agree-
ment prohibiting disclosure to non-study team members
of any individual-level information including TB diagno-
sis and HIV status.
The study has a detailed monitoring plan involving
regular staff visits to project sites and quality assurance
activities related to the routine project activities. The
global PI, global co-investigator/trial manager and the
regulatory officer carry out regular study monitoring to
ensure the study is being implemented with fidelity to
protocol.
A Scientific Advisory Committee (SAC), made of
pediatric TB experts who are external and independent
from all project collaborators, provides scientific over-
sight to the study and reviews the study progress
regularly.
We have identified a few risks and limitations pertain-
ing to the study implementation.
MoHs in the two countries may be willing to start inter-
ventions to promote active case finding (as already in the
implementation phase in Kenya) and integrated TB ser-
vices, as recommended by WHO. These national activities
will not be slowed down in the study sites. Information re-
garding the standard-of-care and its evolution throughout
the standard-of-care period will be carefully reported. The
stepped-wedge design will allow taking into account tem-
poral trends which could result in these standard-of-care
changes during the pre-implementation period.
Chart abstraction data depends on the quality of data
collected by facilities as part of routine data collection.
Thus, it is possible we will have missing or incomplete
data for some of the records in the pre-intervention
phase. Our staff is available to support facility based
health workers in collecting data as requested and we
are monitoring carefully the quality early on in the
process to correct any quality issues that may arise.
We calculated the sample size according to an opti-
mistic estimate of the number of pediatric TB cases di-
agnosed, either in the standard-of-care or intervention
phase. If the number of cases is lower than expected, the
study may be underpowered to show the impact of the
intervention on TB case detection.
Finally, an initial increase in case finding may be ob-
served at study initiation because we may capture preva-
lent cases not diagnosed since then, though this effect
may be less pronounced than in adult studies. We also
expect that the start of the study, with the use of new
TB registers and M&E forms, will be associated with in-
creased awareness about TB and may thus improve TB
diagnostic access, even before roll-out of the interven-
tion. This confounding effect is likely to be unavoidable
and will need to be taken in consideration while inter-
preting results.
In summary, the INPUT study uses a robust method-
ology and its results are expected to inform innovative
strategies on organization of TB care. The study results
will be shared with national and international clinicians,
program implementers, scientific audiences and policy
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makers through reports, presentations and manuscripts.
Demonstrating a benefit of integrated child TB care on
TB case detection will provide strong supportive evi-
dence to catalyze the widespread implementation of this
intervention across Africa.
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